Medical Equipments Reviews

Archive for the ‘Cancer Detection Instrument’ Category

Bogotá was presented at the first medical device that will help dentists and physicians in the detection of oral cancer. Unlike other diagnostic tools, this equipment allows specialists to detect the early signs and stages of pre-cancer and oral cancer, which often go unnoticed in conventional visual examination. revolutionized the technology for early detection of oral cancer, Cali this company offers the latest generation of diagnostic tools that will change the field of diagnosis for physicians and dentists with Identafi ™ 3000 ultra system specially designed for use by dentists, oral surgeons, periodontists, general practitioners and otolaryngologists mainly consists of three items: – Portable lighting device with three different colors of light (wavelengths). – Lenses specially designed to enhance the appearance of atypical areas. – disposable cover to prevent the spread of infections. In Colombia are not yet known statistics about the incidence of this disease in the population or treatments for Carlos Gairo Colombian pathologist College of dentists, “it is important to generate awareness campaigns oral patients to come to your dentist and you require this test” and that without the help an effective and economical device for dentists, doctors and specialists in oral hygiene, have been waging an unequal struggle against a silent murderer: oral cancer, which has reached epidemic proportions, with an annual increase of 11% in the U.S. due in part to practices such as oral sex.

The ultra Identafi ™ 3000 allows physicians and dentists to identify morphological and biochemical changes in soft and hard tissues of the oral cavity and head and neck. This system emphasizes visually these changes with different types of lighting. “Oral cancer kills one person every hour of every day in the U.S. The only way to stop it is through early detection, which requires the participation of doctors and dentists in this effort, “said Zuluaga. “While working on sensitive and immediate diagnosis of precancer and cancer. The medical community has an urgent need for technologies that not only offer high sensitivity, specificity and efficiency must also be economical enough for all medical and dental clinics can offer. “, Said Andrew F. Zuluaga, President of Andean Trimira SAS device was made ​​in the course of the show Meditech 2010.

The prostate cancer clinically detectable is the most common cancer in men over 50 years of age in the U.S., and the second leading cause of cancer death in men. Approximately 30% of men over age 50 are asymptomatic foci of prostate cancer recognizable in the autopsy series. However, it is estimated that the risk of a man of 50 years to develop a clinically relevant prostate cancer has been estimated at about 10%, while the risk of dying from prostate cancer is approximately 3%.

The implementation of programs for early detection of prostate cancer is very controversial, in Spain, the number of males potentially tributaries of the program over five million. Several screening programs, and including the American Cancer Society have shown that between 85% and 93% of cancers detectable with current methods is clinically important, ie, they are likely to progress and cause damage to individual. In addition, tumors detected from the use of PSA (prostate specific antigen) are more likely to be confined to the organ. When used in screening programs, patients with prostate cancer detected at an earlier stage than when they are symptomatic.

Benign prostatic hyperplasia
Moreover, it should be noted that benign prostatic hyperplasia (BPH) is the most common benign tumor in men over 50 years, and the second cause of admission for surgery. It is therefore advisable to assess clinically, albeit brief, in this age group. In fact, 70% of patients older than 70 develop BPH, of which between 35 and 40% suffer clinical prostatism due to cervico-urethral process. Read the rest of this entry »

Recent studies have opened the debate on the benefits of these diagnostic methods, especially the PSA test.
A couple of weeks the New England Journal of Medicine published two studies that call into question the effectiveness of screening for prostate cancer, which kills about 1,500 Chileans year, making it the second leading cause of cancer death in men.

One of the studies conducted in 76,693 men in the U.S. revealed that mortality rates did not decrease in those undergoing the PSA test and DRE. Meanwhile, a European study conducted in 182,000 men, which only provides for the screening with prostate specific antigen test, it concluded that 20% reduced mortality rates from prostate cancer.
These diagnostic methods, including screening programs since the year 88, are the most used around the world to research the disease. Digital rectal examination is often supplemented with the test of prostate specific antigen (PSA), an enzyme that normally occurs in all prostates and ‘escapes’ into the blood when the gland is affected, including when it comes to cancer .

Both tests are aimed primarily at men over 45 who are at greatest risk, together with a family history and those who maintain a diet with high fat intake.

Dr. Paul Bernier, Chief of the German Urological Clinic, says these tests are actually useful and that the published studies must be understood within the context in which they were made. Read the rest of this entry »

According to investigators, the importance of this study is that it is the first that has investigated the association between taking aspirin during adulthood and breast cancer risk. The findings provide evidence that their use during adulthood could bring benefits. ” In fact, findings have revealed an inverse association between aspirin consumption and the risk of breast cancer, especially in women who drank two or more tablets.

The study analyzed both the frequency of monthly use of aspirin as the number of tablets in each shot. The results showed “a 20% decrease in the risk of developing breast cancer among women who said they had taken low dose aspirin during the year preceding the study.” In addition, patients who consumed two or more tablets were suffering the largest decline, to 26%.

The benefit of aspirin was recorded throughout all decades of life, while reducing the risk of breast cancer was higher in the seventh, ie the group of women aged between 61 and 70 years, reaching 27%. The following age groups with better percentages were between 51 and 60, and between 31 and 40, with 21%.

In addition to the parameters of frequency of use and number of tablets, the study also took into account various risk factors in breast cancer, as body mass index, the physical exercise, or family background and as patients taking NSAIDs because of other diseases such as hypertension, heart disease and / or cerebrovascular disease, diabetes or arthritis.

Although it is still unclear the mechanism by which aspirin may act on the tumor, the authors of this study shows that chronic inflammation may play an important role in carcinogenesis or initial tumor formation in several organs, including breast, and nonsteroidal antiinflammatory drugs (NSAIDs) are proving to have preventive effects by inhibiting cyclooxygenase-2 (COX-2) and prostaglandins (molecules involved in inflammation).

This study adds to previous work done in this regard, as conducted by the Brigham and Women’s Hospital and Harvard Medical School (USA) 2 by more than 4,000 women, published in the Journal of Clinical Oncology, and according to the which ‘the regular consumption of aspirin may increase the survival of women diagnosed with breast cancer and reduce the risk of metastasis by 50% compared with those who do not use this drug on a regular basis. ” Specifically, this study revealed that the risk of metastasis and death from breast cancer in women taking aspirin two to five days a week were 60% and 71% lower, respectively. In patients taking aspirin for six to seven times per week, these percentages were found to be 43% and 64%.

This latest study by the School of Public Health and Health Professions at the University of Buffalo (USA) continues to advance knowledge of aspirin in the oncology sector, although this does not mean you can extrapolate your daily intake for this purpose. This is not an indication of the drug approved in Spain.

Before the publication of certain information that question the validity of mammograms in reducing mortality rates from breast cancer, the Spanish Federation of Breast Cancer makes the following points:

or regret that for some reason interested, any news broadcast is put into question the benefits of mammography. Fortunately, experience and sound scientific data confirm that mammography remains today the best tool to detect breast cancer and therefore the need for women to come to the early detection campaigns when called to get a mammogram .

or How old? There is a fairly general consensus on the age group to begin screening campaigns. That stretch is between 50 and 69, although some Autonomous Communities who start screening at age 45. Certainly the trend is to begin at age 45, but must be the scientific community to confirm the benefits of revised downwards the reference age to begin screening.

There will be individual cases or where because of family history to detect any abnormality, or other circumstances, the starting age is not a determining factor for a mammogram, but must be the health professionals to guide women in either direction. Health professionals have to be our best allies against the possibility of a breast cancer screening.

the campaigns for early detection of breast cancer should be promoted by public health system, with free access, continued over time, equipped with the necessary resources for quality control, developed by trained and evaluated performance, including participation rates, which should be above 80% of the persons summoned. Read the rest of this entry »

Detecting a tumor early in its development, in addition to regular medical examinations and a healthy lifestyle are the keys to various oncology specialists explained to lanacion.com, following the death of the driver model and Patrick Miccio, one of the major aspects of the fight against breast cancer in the country.

Oncologists consulted agreed that the smaller the tumor, the more likely healing. And put the figure of 90 to 95 percent, provided a diagnosis very early, making it possible to detect the tumor when it has grown over two inches in the breast and presents no nodal involvement.

“When it comes to prevention against breast cancer should speak of two types: primary prevention, which includes the care that should lead a person through the adoption of healthy eating and healthy weight, physical activity as well as least 30 minutes per day, and campaigns and measures by the State to have a healthy society. On the other hand, attention should be secondary prevention, covering preventive medical examinations to detect possible tumor when it is too small ” , told lanacion.com Dr. Antonio Lorusso, an oncologist and medical director of Lalcec, Argentina’s League Against Cancer.

The expert stressed the importance of women to have annual or biennial mammography from age 40 (at 30 those who have had a family history), since it is the most effective instrument to detect a possible tumor in its early stages and is curable. “Finding cancer in situ in time, means that cancer is curable, which can be removed through a small surgery, which involves no mastectomy (breast removal) and that this woman may in the future to nurse a baby without any problem, “said Lorusso-Gynecology professor at UBA, which is not ruled out other methods of diagnosis, including physical examination by touch or a breast ultrasound. Read the rest of this entry »

Two teams of researchers are experimenting with methods more accurate and less invasive for the detection of colon cancer, reported the University of Michigan (UM).

The professor of internal medicine and biomedical engineering at UM, Thomas D. Wang, did research, recorded this week in the journal Nature Medicine, reveals a new technique that could detect colon cancer.

The method includes the topical application of a peptide labeled with a fluorescent agent. The peptide is designed to identify pre-cancerous changes in the colon. Then, using a special microscope that fits inside a standard medical endoscope, the physician can detect these lesions.

“There has been a huge effort to get to screening patients for polyps that can be seen with a white light endoscope,” Wang said

“But if pre-cancerous lesions or cancer are flat not be seen with common detection techniques. Therefore we use advanced imaging techniques that seek molecular targets rather than structural changes,” he added. Read the rest of this entry »